Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel in Painful Diabetic Neuropathy
NCT00505284Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2007
- Primary completion
- Jul 2008
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of perampanel in diabetic neuropathy (5 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Change in Average Pain Scores From Baseline to Week 15/End of Treatment (EOT), Responder Rate: Analysis of the Change in Pain Score From Baseline to Week 15/EOT in Subjects Who Had at Least a 30% Reduction in Pain Score and 2 more. Started Jun 2007; status: completed.
02
Drugs
perampanel
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on NCT00505284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00505284.